First clinical trial on HER-2-negative breast cancer with nintedanib shows promising results

10 septiembre 2014

The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumors in 50 percent of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.